Apomorphine is a medication generally used for symptoms that interfere with daily functioning in individuals with advanced Parkinson's disease. The medication is considered relevant in the therapeutic area focusing on symptoms of increased neurological or muscular activity and conditions involving episodic or fluctuating manifestations associated with advanced Parkinson's disease.

This application is commonly used across conditions presenting with acute episodes where a patient experiences symptoms that create noticeable physiological strain. It is applied in addressing symptoms such as hypokinesia (slowness), muscular rigidity (stiffness), and episodes of freezing of gait.

“This supportive therapeutic use contributes to easing the overall symptom load for patients needing symptomatic support.”

The medication is relevant in clinical settings that involve acute or unstable symptom patterns. By addressing these acute symptoms, it may assist with maintaining functional stability and helps with managing episodes of heightened physical discomfort. This supportive use may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Acute Motor Symptoms
Supports the management of symptoms that interfere with daily functioning during episodes of heightened physiological stress.

The eligibility for apomorphine use is strictly defined by government regulatory documents based on patient status, age, and concomitant medications. The medicine is formally indicated for adults with advanced Parkinson's disease experiencing acute "off" episodes.

Eligibility Status	Applicable Population
Contraindicated	Patients using drugs of the 5HT3 antagonist class, including antiemetics such as ondansetron, due to risk of profound hypotension and loss of consciousness.
Contraindicated	Patients with known hypersensitivity or allergy to apomorphine or any component of the formulation, including sulfites/sodium metabisulfite.
Contraindicated	Children and adolescents under 18 years of age; safety and efficacy have not been established.
Contraindicated	Patients with severe hepatic insufficiency or severe renal impairment (varies by formulation/region).

Use is not recommended during pregnancy, as there are no adequate human data and animal studies suggest potential fetal harm. Patients with pre-existing cardiac disease or risk factors for QTc prolongation require caution. Elderly patients (65 years and older) may be more susceptible to adverse events and require cautious dose management. Additionally, patients who develop clinically significant orthostatic hypotension following a test dose are generally not considered candidates for treatment.

Interaction Map: Interactions with other medicines and products — official regulatory information for Apomorphine

Interaction scope Medicinal product categories with documented interactions: Dopamine Antagonists, Antihypertensive Medications, Vasodilators, 5HT3 Antagonists, and Drugs Prolonging the QTc Interval. Specific interacting medicines (if explicitly listed): Ondansetron, Granisetron, and other 5HT3 Antagonists; Trimethobenzamide (anti-emetic); Metoclopramide; and Sublingual Nitroglycerine. Mechanistic basis of interactions (only if stated in label): Pharmacodynamic potentiation of hypotensive effects; Pharmacodynamic antagonism of therapeutic effect; Additive QTc prolongation risk. Timing-based interaction rules (if applicable): The anti-emetic Trimethobenzamide is recommended to be started 3 days prior to Apomorphine initiation and should be continued generally no longer than two months. Population-specific interaction notes (if applicable): Elderly and/or debilitated patients require extra caution during therapy initiation due to potentially increased susceptibility to hypotensive effects. Interaction-related restrictions: Alcohol should be avoided due to the increased incidence and extent of hypotension and sedation.

Interaction classifications (high-level) Interaction severity classification (as defined in official documents): Contraindicated Combination (5HT3 Antagonists); Significant Interaction Requiring Caution/Monitoring (Antihypertensives, QT-prolonging drugs). Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and Summary of Product Characteristics (SmPC). Interaction-context constraints (as defined in official documents): The profile includes constraints based on combined effects on blood pressure regulation and cardiac QTc interval, as well as a mandatory procedural rule for anti-emetic pre-treatment timing.

Resulting interaction structure Official interaction statements:

• Co-administration of 5HT3 antagonists is contraindicated due to the risk of profound hypotension and loss of consciousness.
• Antihypertensive medications and vasodilators increase the risk for hypotension.
• Concomitant use with drugs that prolong the QTc interval increases the risk of additive QTc prolongation.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documents define Apomorphine’s interaction profile primarily through pharmacodynamic risk associated with its effects on blood pressure and cardiac repolarization, resulting in contraindicated combinations and use-with-caution classifications. The profile explicitly includes a procedural constraint that mandates specific timing for the required anti-emetic and restricts the co-consumption of alcohol due to its effect on blood pressure. This structure strictly outlines the substances, categories, and conditions where the drug's co-use is restricted or prohibited.

Apomorphine is a lipophilic, non-ergoline dopamine agonist that readily crosses the blood-brain barrier for selective accumulation in the Central Nervous System. It acts primarily by stimulating post-synaptic dopamine receptors in the nigrostriatal, limbic, and hypothalamic pathways. It functions as a full or partial agonist at both the D1-like (D1 and D5) and D2-like (D2, D3, and D4) families of G protein-coupled receptors, with higher affinity for the D2-like subtype.

Activation of the D1-like family stimulates adenylate cyclase via Gs protein coupling, increasing intracellular cyclic AMP (cAMP) levels. Conversely, activation of the D2-like family inhibits adenylate cyclase via Gi protein coupling, which decreases intracellular cAMP levels. The net result of this dual-receptor modulation is a restoration of dopaminergic signaling. Apomorphine also exhibits an antagonist interaction type at 5-HT2 and alpha-adrenergic receptors. System-level physiological consequences include modulation of motor control centers in the brain, influencing efferent signals within the motor pathways.

How to Use Apomorphine: Official Administration Guidelines

Apomorphine is available as a subcutaneous injection and a sublingual film for on-demand use to treat 'off' episodes. Adherence to official instructions for administration, dosing, and frequency is required.

Administration Details

Administration Scope	Subcutaneous Injection	Sublingual Film
Route of Administration	Under the skin (subcutaneous) only. Do not inject into a vein.	Under the tongue (sublingual) only. Do not cut, chew, or swallow.
Preparation	Visually inspect solution; do not use if discolored, cloudy, or contains particles.	Place entire film under the tongue and allow it to dissolve completely (approx. 3 minutes). Moistening the mouth with water beforehand is recommended.
Dosing Schedule	Starting doses are typically 1 mg or 2 mg and must be individualized. Maximum recommended single dose is 6 mg.	Starting dose is typically 10 mg. The dose is individualized, with a maximum single dose of 30 mg.

Procedural Rules

Initial Administration: The first dose and any subsequent dose adjustments (titration) must be performed under the supervision of a healthcare professional. This is a requirement for both injection and sublingual film products.

Timing and Frequency: The medicine is used as needed when an 'off' episode occurs. For both forms, doses must be separated by a minimum of two hours, and treatment is limited to a maximum of five doses per day. It is recommended that a concomitant antiemetic (nausea) medication be initiated a few days prior to the first Apomorphine dose, and continued for up to two months.

These official instructions establish the precise parameters for how the drug must be used: administration is restricted to the proper route, dosing is determined by a supervised titration protocol, and the total daily exposure is controlled by set minimum time intervals between doses and a maximum daily limit.

Research Evidence / Overview of studies for Apomorphine

Apomorphine for Off-Episodes (Motor Fluctuations) in Parkinson's Disease

Studies on apomorphine primarily focus on research into its use for managing sudden, unpredictable worsening of Parkinson's symptoms, known as "off-episodes" or motor fluctuations. This research area is the most established for this medication.

The main type of research conducted includes randomized controlled trials (RCTs). These studies compare patients who receive apomorphine to those who receive a placebo (an inactive substance) to see if the drug is associated with a change in the duration or severity of an off-episode. Overall, research has explored whether apomorphine is associated with a more rapid return to a state of improved movement during these sudden off-periods. Findings from these studies have suggested that when apomorphine is administered as an injection at the onset of an off-episode, the time to experience a return to a more manageable state of movement (the "on" state) may be reduced.

Some studies also look at using apomorphine as a continuous infusion (delivered constantly through a pump under the skin) to explore whether it is associated with a reduction in the total amount of time a person spends in the "off" state throughout the day. Research examining continuous delivery has suggested a potential association with a decrease in the overall frequency and severity of off-episodes, and studies have explored whether this delivery method may be a factor in allowing some participants to take lower doses of their other Parkinson's medications.

However, the current research still has limitations. While studies suggest an association with improving movement during an off-episode, there is less long-term evidence looking at how this treatment approach affects a person's quality of life or disease progression over many years. Also, many studies did not specifically look at how the outcomes of the medication might differ based on a person's age or the specific combination of other medications they are taking for Parkinson's disease.

---

Apomorphine for Non-Motor Symptoms

Research investigating apomorphine for symptoms of Parkinson's disease that are not related to movement (non-motor symptoms) is much more limited than for movement issues. These symptoms can include changes in mood, sleep problems, or cognitive difficulties.

The available studies are often smaller and may not be large randomized controlled trials. Research has explored the possibility of an association between apomorphine and changes in symptoms such as impulse control disorders, excessive daytime sleepiness, or pain in people with Parkinson's disease. For example, some small studies have explored whether a continuous infusion of apomorphine is associated with changes in excessive daytime sleepiness and certain aspects of impulse control.

However, the evidence is not yet robust enough to draw firm conclusions for these non-motor issues. Findings are often mixed, and it is unclear if the observed changes are a direct result of the medication or an indirect result of better motor control. The research remains preliminary, and there are significant gaps in our understanding of apomorphine's role in addressing the full range of non-motor symptoms associated with Parkinson's disease.

---

Apomorphine for Restless Legs Syndrome

Apomorphine has also been studied as a subject of research for severe Restless Legs Syndrome (RLS). This condition involves an uncomfortable urge to move the legs, often worse in the evenings.

The research exploring this use is sparse, typically involving small, short-term studies or case reports (detailed reports about a few individual patients). Early findings suggested that research could explore whether apomorphine is associated with a change in RLS symptoms, particularly in people who have not responded well to other common treatments.

However, the lack of large, high-quality studies makes it impossible to say for certain whether apomorphine is associated with consistent outcomes for RLS. The available evidence is considered highly limited, and larger, more rigorous research is needed to investigate any potential benefits and to better understand who might be included in future studies exploring this treatment approach.

Key Studies & References NICE Guideline NG71: Parkinson's disease in adults: diagnosis and management

Common questions about Apomorphine (FAQ)

---

Q: What is the difference between Apomorphine and other Parkinson's medicines?

Apomorphine is described in official documents as a dopamine agonist used specifically as an acute rescue treatment for sudden 'off' episodes. This is different from many other medicines for Parkinson's, which are taken regularly for daily maintenance therapy.

---

Q: How quickly does Apomorphine start working after it's used?

Apomorphine is engineered to be a fast-onset medication for acute situations. Clinical studies have specifically focused on measuring how quickly the treatment is associated with the patient returning to a manageable 'on' state once an 'off' episode begins.

---

Q: How long do the effects of Apomorphine usually last?

The official dosing instructions state that no two doses should be administered sooner than two hours apart. The medication is used for the acute, intermittent management of sudden 'off' episodes as they occur, not for continuous, long-term effect from a single dose.

---

Q: What should I know about the nausea sometimes caused by Apomorphine?

Nausea and vomiting are documented as very common side effects of Apomorphine, which may sometimes be severe. Due to this frequent occurrence, official regulatory documents state that a concomitant anti-nausea medicine (antiemetic) should be initiated a few days prior to the first Apomorphine dose.

---

Q: Can older adults use Apomorphine safely?

Official product information notes that older adults (aged 65 and above) may be more susceptible to adverse effects, such as a higher risk of confusion. Caution is therefore required, and official documents note the need for careful dose management when the medicine is initiated in this population.

---

Q: Is it true that Apomorphine is related to morphine?

Apomorphine is chemically classified as an Aporphine alkaloid, meaning it is derived from the morphine molecule. However, official sources clarify that it is a non-narcotic drug and its therapeutic function is exclusively focused on stimulating the brain's motor control system.

---

Q: What is the 'on-off' phenomenon in Parkinson's, and how does Apomorphine relate to it?

The 'on-off' phenomenon describes the sudden, unpredictable switch between periods of good motor control ('on' time) and periods when motor symptoms, like stiffness and slowness, suddenly worsen ('off' episodes). Apomorphine is specifically indicated by regulatory bodies for the acute, intermittent treatment of these sudden 'off' episodes.

---

Q: What is the role of a healthcare team in managing Apomorphine use?

The initial use of Apomorphine is highly regulated: the first dose and any subsequent dose adjustments (titration) must be performed under the direct supervision of a healthcare professional. The team's role during this phase is to monitor the patient for potential adverse effects, specifically focusing on blood pressure and pulse changes.

---

Q: What is the typical monitoring required when someone starts Apomorphine?

Monitoring at the start of treatment is essential and focuses on the potential for the medicine to cause low blood pressure (hypotension). This involves closely checking blood pressure and pulse after a test dose. Separately, an ECG (a heart test) may be recommended if the patient is taking other medicines known to affect the heart's rhythm.

---

Q: Does Apomorphine make you feel sleepy or drowsy?

Drowsiness or unusual sleepiness (somnolence) is documented as a common side effect in official prescribing information. Regulatory warnings also note that patients have reported suddenly falling asleep without warning while engaged in daily activities.

---

Q: Are there any common over-the-counter medicines that interact with Apomorphine?

Regulatory documents advise informing a healthcare professional about all products being used, including prescription and over-the-counter medicines, vitamins, minerals, and herbal supplements. While the official interaction map focuses on specific classes of drugs, this general caution is provided for all co-administered products.

---

Q: Can Apomorphine change your mood or behavior?

Official warnings state that the medicine has been associated with new or worsening mental status and behavioral changes. These documented effects include hallucinations, psychotic-like behavior, and the development of impulsive/compulsive behaviors such as excessive gambling, spending, or eating.

---

Q: Can Apomorphine affect my ability to do things like hobbies or work?

Official warnings state that if a patient experiences significant daytime sleepiness or suddenly falls asleep, they are advised not to drive or participate in any potentially dangerous activities. Regulatory guidance states that the medicine should be discontinued if these serious effects occur.

---

Q: What happens if I miss using Apomorphine?

Apomorphine is intended for on-demand use when an 'off' episode occurs, not for a scheduled regimen. The official instruction is not to use another dose sooner than two hours after the last administration, even if an 'off' episode returns.

---

Q: Is Apomorphine only available as an injection or a pump?

The medicine is available in various forms: a subcutaneous injection and a sublingual film are used for acute, intermittent 'off' episodes. A version for continuous subcutaneous infusion, which requires the use of an infusion pump, is also available for ongoing management.

---

Q: What if I experience sudden sleep attacks while using Apomorphine?

Official warnings explicitly state that patients have reported suddenly falling asleep without prior warning while engaged in daily activities. Official warnings state that if this occurs, the medicine should be discontinued, and patients require continued reassessment for daytime drowsiness.

---

Q: Is Apomorphine used to treat tremors?

Apomorphine is officially indicated for the acute management of motor fluctuations or 'off' episodes in advanced Parkinson's disease. These 'off' episodes are characterized by the sudden re-emergence of movement symptoms, which can include tremors, slowness, and muscle stiffness.

---

Q: Can Apomorphine cause muscle stiffness or pain?

While the drug is used to relieve stiffness during 'off' periods, official warnings note a risk of a withdrawal-emergent syndrome if the medication is stopped suddenly. The symptoms of this rare, serious reaction include fever, confusion, and severe muscle stiffness.

---

Q: What are the known risks of stopping Apomorphine suddenly?

Official warnings describe the risks associated with suddenly stopping Apomorphine due to a condition called withdrawal-emergent hyperpyrexia and confusion. This serious syndrome can present with symptoms such as fever, confusion, and severe muscle stiffness.

---

Q: Are there specific instructions for traveling with Apomorphine?

Official storage and handling instructions for one formulation specify that when traveling, the medicine must be kept within a specific temperature range, typically between 59 F and 86 F (15 C and 30 C). It is also important to protect the product from light.

---

Q: Does Apomorphine cause swelling in the legs or feet?

Swelling of the hands, arms, legs, and feet (medically known as edema) is listed in the official prescribing information as a common side effect, particularly for the injection formulation.

---

Q: Why is a test often recommended before starting Apomorphine?

Testing is recommended prior to the first dose to monitor the potential for the medicine to cause low blood pressure (hypotension). This involves checking blood pressure and pulse after a test dose. Separately, an ECG (heart test) may be recommended if the patient is using other medicines that affect the heart's rhythm.

---

Q: Is it possible for Apomorphine to stop working over time?

Research has explored the potential for long-term effectiveness. Findings from open-label studies suggest that the benefit of reducing 'off' time was sustained for over a year of use in the trial participants, though these studies have limitations.

---

Q: Does Apomorphine interact with common vitamins or supplements?

Official documents advise patients to inform their healthcare professional about all products used, which includes vitamins and supplements. This caution is given because the established interaction profile, which focuses on specific classes of drugs, may not contain a complete list of every substance.

---

Q: Can Apomorphine affect eyesight?

Blurred vision is listed as an adverse reaction in the official prescribing information.

---

Q: Why is it important to keep track of my 'on' and 'off' times when using Apomorphine?

Tracking 'on' and 'off' times is the primary method used in clinical trials to objectively measure the drug's effectiveness. The goal of treatment, as described in regulatory documents, is to reduce the total amount of daily 'off' time and improve the patient's condition.

How to Store and Dispose of Apomorphine

Apomorphine injection must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and kept in its original carton. It is mandatory that the medication is not frozen and remains out of the reach of children.

---

Stability and Disposal

The solution is for single use only. Any unused portion in an opened vial or cartridge must be discarded immediately. Do not dispose of the medication in household trash or down the toilet. All unused product, including used needles and sharp devices, must be disposed of in an FDA-cleared sharps disposal container and according to local pharmaceutical waste requirements.